1. Introduction {#sec1}
===============

Severe neurological complications from seasonal influenza, including influenza-associated encephalopathy/encephalitis (IAE), cause considerable morbidity and mortality in healthy children, and those with pre-existing neurological disease.[@bib1], [@bib2], [@bib3] Recent estimates indicate the annual incidence of IAE in Australia is 2.8 per 1,000,000 in children under 14 years, with around 1% of hospitalized influenza cases associated with IAE.[@bib4] Other populations show similar or higher incidence, with Japan\'s annual incidence of IAE recorded as 6--11/1,000,000.[@bib2], [@bib5] Neurological complications attributed to influenza range from a mildly altered mental state, vertigo and brief febrile seizures to life threatening complications such as status epilepticus, meningitis, stroke, and demyelinating disease.[@bib1] Antiviral agents, predominantly neuraminidase inhibitors, and immunomodulatory treatments (corticosteroids, intravenous immunoglobulin), are used to treat patients with influenza-associated neurological disease but there is limited evidence on their efficacy.[@bib6] While it is thought that more extensive changes on MRI correlate with disease severity[@bib7] there are no other available biomarkers that predict outcome.

The Australian influenza season typically occurs between July and October. The 2017 season saw the highest levels of influenza reported since the 2009 pandemic year.[@bib8] The authors of this report noted an apparent increase in IAE and other severe neurological complications during 2017. Here, we describe the clinical presentation, laboratory testing, neuroimaging, treatment and short-term outcome of these cases. In addition, we observed elevated cerebrospinal fluid (CSF) neopterin -- a marker of central nervous system (CNS) inflammation -- amongst children with IAE that has not previously described. We compared the frequency of IAE during the 2017 influenza season with previously published incidence estimates.

2. Materials and methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

We identified children aged 0--14 years, with evidence of influenza and associated severe neurological disease including status epilepticus or moderate to severe encephalopathy, admitted to two paediatric hospitals which comprise the Sydney Children\'s Hospital Network, the largest paediatric network in Australia. Cases were ascertained between April 1st and October 31st, 2017.

2.2. Inclusion and exclusion criteria {#sec2.2}
-------------------------------------

At the Children\'s Hospital at Westmead, cases were identified from those recruited under pre-existing surveillance studies: the Australian Childhood Encephalitis study (ACE), and the Influenza Complications Network (FluCAN) surveillance study.[@bib4], [@bib9] At Sydney Children\'s Hospital, children were identified from neurology consultation databases. Children were included if they required hospital admission and consultation from a Paediatric Neurologist for a neurological complication or worsening of a pre-existing neurological condition due to proven influenza. All children included either presented with status epilepticus (for 30 min or longer) or reached level 2 diagnostic certainty on the Brighton encephalopathy score.[@bib10] Children were excluded if: influenza was not confirmed, neurological symptoms were mild, hospital admission was not required, and when an alternative diagnosis could better explain the presentation. Data were retrospectively collected from electronic medical records.

2.3. Presenting characteristics, biochemical and neuroimaging {#sec2.3}
-------------------------------------------------------------

We collected demographic data, presenting clinical characteristics, intensive care unit (ICU) admission, and length of stay, laboratory results including CSF testing, and influenza testing. CSF analysis included cell count, protein, glucose, microscopy, lactate, oligoclonal bands, neopterin and influenza PCR. An elevated CSF neopterin result was defined as \>30 nmol/L.[@bib11] Electroencephalogram reports and brain magnetic resonance imaging (MRI) (T2 weighted, FLAIR and diffusion weighted imaging) were assessed by a neurologist (S.P.) and neuroradiologist (C.C.H.). The neuroradiologist was blinded to diagnosis during review of the MRI.

Influenza was most commonly acutely diagnosed through the detection of influenza RNA in respiratory samples. Both hospitals used multiplex PCR assays (Seegene, South Korea) which detected up to 16 respiratory viruses. The assay has targets for both influenza A and B and was performed daily with a turnaround time of 1--2 days. At Sydney Children\'s Hospital, the assay also had targets for subtypes of influenza A: H3 strains and the pandemic strain H1N1/09. When influenza serology was requested to diagnose a recent influenza illness, this was performed using a complement fixation assay (Virion, Germany).

2.4. Treatment and outcomes {#sec2.4}
---------------------------

Treatment given including oseltamivir, empiric aciclovir, or 3rd generation cephalosporins, IVIg, corticosteroids, and plasmapheresis were recorded. Time from admission to commencement of oseltamivir was recorded. Each case was assigned a modified Rankin scale (mRS) based on the examination at presentation and discharge from hospital.[@bib12] The mRS ranges from 0 (no symptoms) to 6 (death). A poor outcome was an mRS score of \>2 which indicates at least moderate disability requiring assistance.

2.5. Statistics {#sec2.5}
---------------

The relation between categorical variables was investigated using the two tailed Fisher exact test. The Mann--Whitney *U* test was used to determine the relation between continuous variables.

Ethics approval was granted by the Sydney Children\'s Hospitals Network Ethics Committee (LNR/17/SCHN/497).

3. Results {#sec3}
==========

3.1. Participants {#sec3.1}
-----------------

Twenty two children were included in this case series; 59% (13/22) were female. The median age at presentation was five years (range: 1.25--14 years). Eight children (36%) had pre-existing epilepsy and/or developmental delay. One child had an immunodeficiency (hypogammaglobulinemia) and receives monthly IVIg. This child, who presented with status epilepticus, was the only child recorded as having received the seasonal influenza vaccination.

Eleven children (50%) met level 2 Brighton criteria for encephalitis and were designated as influenza associated encephalopathy/encephalitis (IAE).[@bib10] Two children with IAE had previous episodes of acute disseminated encephalomyelitis (ADEM) with complete clinical and radiological recovery ([Table 3](#tbl3){ref-type="table"} cases 1&2). One child had mosaic tetrasomy X, while another had epilepsy and developmental delay. The remaining 11 children in our series had status epilepticus. In contrast to the children with IAE, over half of this group (*n* = 6) had pre-existing neurological disease including two children with refractory genetic epilepsies (Dravet syndrome and CDKL5).

3.2. Presenting characteristics {#sec3.2}
-------------------------------

The majority of children had a fever (82%) and two-thirds had respiratory symptoms. Half presented with neurological symptoms within two days of onset of their influenza illness. Sixteen children (73%) presented with an altered level of consciousness. Seizures occurred in 19 children (86%) at any stage of illness and status epilepticus was frequent (*n* = 17, 77%). Other neurological findings at presentation were weakness (*n* = 9, 41%), pyramidal signs (*n* = 8, 36%), movement disorder (*n* = 7, 32%) and ataxia (*n* = 6, 27%). Hallucinations, meningism, cranial neuropathy and pupillary changes were infrequent (\<20%).

3.3. Biochemical and neuroimaging {#sec3.3}
---------------------------------

The majority of children (*n* = 18, 82%) had influenza A. Of those sub-typed (*n* = 8) half were H1 (2009) and half were H3. Four children had other respiratory pathogens co-identified on NPA (rhinovirus, coronavirus, *Mycoplasma pneumoniae*). Enterovirus was detected in the NPA of one child but was absent in CSF. One blood culture was positive for *Staphylococcus epidermidis*, and this was assessed to be a contaminant.

Lumbar puncture was performed in 14 children where it was considered clinically indicated ([Table 2](#tbl2){ref-type="table"}). Of those who did not have a lumbar puncture performed most were children who presented with status epilepticus alone, usually with known pre-existing epilepsy. One case, with acute necrotising encephalopathy (ANE), who was deemed to be too unwell to undergo a second lumbar puncture for measurement of neopterin. Where sampled, CSF showed pleocytosis and elevated protein in only a third (each *n* = 5). Influenza PCR on CSF was positive in 1 of 5 children tested, in an immunocompetent previously well 10 year old. The CSF neopterin was elevated in 9 of 11 children tested; in seven children it was considerably elevated ranging from 74 to 669 nmol/L (normal \< 30 nmol/L), one had a borderline result (34 nmol/L). CSF neopterin was measured in one child presenting with status epilepticus and was 31.75 nmol/L (borderline result). While most children with IAE had a raised CSF neopterin (8/10, 80%), only three had CSF pleocytosis (10, 18, 19 cells/mm^3^) and two had an elevated CSF protein (0.7 g/L and 7.0 g/L). Oligoclonal bands were measured on serum and/or CSF in 10/11 children with IAE and were not present in any. Some children with IAE had anti-neuronal antibodies testing performed on serum and/or CSF, usually NMDA and VGKC ([Table 3](#tbl3){ref-type="table"} ). These were negative apart from two cases with mildly elevated anti-thyroid antibodies. Other routine laboratory data were normal or only mildly abnormal in most children ([Table 1](#tbl1){ref-type="table"}).Table 1Demographics and clinical features of children with Influenza and severe neurological complications admitted to the admitted to the Sydney Children\'s Hospitals network during the 2017 influenza season.Table 1CharacteristicIAE,[a](#tbl1fna){ref-type="table-fn"}*n* = 11 (%)SE,[b](#tbl1fnb){ref-type="table-fn"}*n* = 11 (%)*p*-ValueFemale sex6 (55)7 (64)1.0Age (median, range)6 (15 months--14 years)3 (20 months--12 years)0.36Pre-existing epilepsy2 (18)6 (55)0.18Received seasonal influenza vaccine0 (0)1 (9)--Days between respiratory symptoms and neurological presentation in days (median, range)4 (1--21)3 (1--14)0.663Seizures8 (73)11 (100)0.21Status epilepticus6 (55)11 (100)0.04Influenza A positive (NPA[c](#tbl1fnc){ref-type="table-fn"} PCR/serology)8 (73)10 (91)0.59Influenza B positive (NPA[c](#tbl1fnc){ref-type="table-fn"} PCR)3 (27)1 (9)0.59CSF influenza PCR positive1/5 (40)0/0 (0)--CSF pleocytosis (*n*, %, range) \[WCC \> 5.0 × 10^6^/L\]5 (45) \[0--242\]0/3, \[0--1\]0.26Elevated CSF protein (*n*, %, range) \[0.15--0.45 g/L\]5 (45), \[0.19--7.0\]0/3 \[0.10--1.17\]0.26CSF neopterin elevated (*n*, %) \>308/10 (80)[d](#tbl1fnd){ref-type="table-fn"}1/1 (100)[e](#tbl1fne){ref-type="table-fn"}0.45[^1][^2][^3][^4][^5][^6]Table 2Treatment and outcome of children with Influenza and neurological complications admitted to the Sydney Children\'s Hospitals network during the 2017 Influenza season.Table 2OutcomesIAE[a](#tbl2fna){ref-type="table-fn"} (*n* = 11)SE[b](#tbl2fnb){ref-type="table-fn"} (*n* = 11)*p*-ValueAdmitted to intensive care9 (82)5 (45)0.18Required mechanical ventilation7 (64)2 (18)0.08Treatment[c](#tbl2fnc){ref-type="table-fn"} Oseltamivir7 (64)6 (55)1.0 3rd generation cephalosporin11 (100)8 (73)0.21 Aciclovir8 (73)6 (55)0.66 Intravenous immunoglobulin7 (64)0 (0)0.004 High dose corticosteroids9 (82)0 (0)\<0.001 Plasmapheresis1 (9)0 (0)1.0 Anticonvulsant8 (73)11 (100)0.21Days in ICU (mean, range)7.7 (1--37)2 (1--3)0.03Days in hospital (mean, range)33.5 (5--108)4.8 (2--14)0.001Outcome at discharge Death1 (9)0 (0)1.0 Abnormal/Poor[d](#tbl2fnd){ref-type="table-fn"}7 (64)0 (0)0.004 Mean mRS at admission0.21.70.086 Mean mRS at discharge3.32.10.126 Mean change in mRS3.10.40.001[^7][^8][^9][^10][^11]Table 3Case summaries of children with Influenza-associated encephalitis (IAE) in Sydney, 2017.Table 3CaseAge (years) sex (M/F)Clinical syndromeFlu typeMRI findingsCSF white cell count (×10^6^/L)Influenza positive on CSF.Neuronal/inflammatory antibody testingICUTreatment givenNeopterin (nmol/L)mRS (Baseline; discharge)114y, FEncephalitis,\
Previous cerebellitis aged 7 years, full recovery.BT2 hyperintensity involving the margins of the lateral ventricles, clastrum, mammillary bodies, and caudate nucleus \[[Fig. 1](#fig1){ref-type="fig"}G and H\]1Not performed.NMDAR, VGKC, NMO, TPO antibodies -- negative.Yes3rd generation cephalosporin\
Oseltamivir\
Aciclovir\
IVIG\
Corticosteroid\
Plasmapheresis1740; 6 (Death)213y, FANE\
Previous ADEM aged 4y, full recovery.AMultiple symmetrical foci of diffusion restriction & T2 hyperintensity in the cerebellum pons, cerebral white matter and basal ganglia. Left thalamic haemorrhage. \[[Fig. 1](#fig1){ref-type="fig"}E\]0Not performed.Not performed.Yes3rd generation cephalosporin\
Oseltamivir\
Aciclovir\
IVIG\
Corticosteroidnone0; 3310y, MHyperkinetic movement disorder.\
Mild cerebral palsy. GMFCS 1.BNormal.3.3Negative.NMDAR, VGKC antibodies -- negative. TPO & thyroglobulin antibodies positive.No3rd generation cephalosporin\
IVIG\
Corticosteroid77.30; 249y, MEncephalitis with focal status epilepticus.\
Previously well.ANormal.3.9Positive.\
Influenza ANMDAR, VGKC antibodies -- negative. TPO and thyroglobulin antibodies positive.No3rd generation cephalosporin\
Aciclovir\
IVIG\
Corticosteroid2030; 157y MEncephalitis with possible PRES\
Previously well.BInitial scan normal. Repeat 5 days later: Cortical and subcortical vasogenic oedema in posterior and anterior watershed areas with a few non-specific foci of restricted diffusion.\[[Fig. 1](#fig1){ref-type="fig"}D\]10Not performed.Not performed.Yes3rd generation cephalosporin\
Oseltamivir\
Aciclovir740; 266y FCerebellitis\
Previously well.AT2 and FLAIR hyperintensities in both cerebellar hemispheres. Enhancement of the cerebellar folia with gadolinium. \[[Fig. 1](#fig1){ref-type="fig"}F\]242NegativeNMDAR, VGKC, GAD, PCA1, PCA2, Hu, Ri, Ma 1&2, amphiphysin antibodies, MOG - negativeYes3rd generation cephalosporin\
Oseltamivir\
Aciclovir\
IVIG\
Corticosteroid160; 474y FAESD, Reye like syndrome\
2 previous episode of status epilepticus, known epilepsy.A (H3)Multiple foci of T2/FLAIR hyperintensity and diffusion restriction in the subcortical white matter of the left frontal and deep white matter of parietal lobes. Reduction in volume of right temporal lobe with hyper intense signal in right hippocampus.\[[Fig. 1](#fig1){ref-type="fig"}A\]0NegativeNMDAR, VGKC antibodies -- negative.Yes3rd generation cephalosporin\
Corticosteroid2012; 584y FEncephalitis\
Mosaic tetrasomy X, cerebral palsy, developmental delay.A (H109)Stable appearance from previous scans. Moderate atrophy of the superior vermis of the cerebellum. Non-specific T2 hyperintensiites in the subcortical white matter.2.7Not performed.Not performed.Yes3rd generation cephalosporin\
Oseltamivir344; 492y MAESD\
Previously well. History of simple febrile seizures.ABilateral restricted diffusion in the peri-rolandic and posterior white matter with sparing of the basal ganglia \[[Fig. 1](#fig1){ref-type="fig"}B\]0Not performed.Not performed.Yes3rd generation cephalosporin\
Oseltamivir\
Aciclovir\
Corticosteroid3170; 3101.3y FHHS\
Previously well.A (H109)T2/FLAIR hyper- intensity and mild diffusion restriction of the left temporal and left occipital lobes. Lacate peak on MRS on the left side. \[[Fig. 1](#fig1){ref-type="fig"}C\]4.1NegativeNMDAR, VGKC, TPO antibodies - negativeYes3rd generation cephalosporin\
Oseltamivir\
Aciclovir\
IVIG\
Corticosteroid6690; 3111.2y MSubcortical myoclonus\
Previously well.\
This child was found to have a mutation in the POLG gene.AInitial scan: non-specific left thalamic T2 hyperintensity.\
Repeat 3 weeks later: Diffusion restriction lateral part of left thalamus. \[[Fig. 1](#fig1){ref-type="fig"}I\]6Not performed.Not performedYes3rd generation cephalosporin\
Aciclovir\
IVIG\
Corticosteroid280; 4[^12]

MRI brain was performed in 15 children and showed new abnormalities in eight (53%), all with IAE. The common acute MRI abnormalities were the presence of T2-FLAIR hyperintensities, diffusion restriction (each, *n* = 8), and gadolinium enhancement (*n* = 4). The spectrum of radiological features are shown in [Fig. 1](#fig1){ref-type="fig"} A--I. Diverse clinico-radiological syndromes were diagnosed including: ANE (*n* = 1), acute encephalopathy with biphasic seizures (AESD) (*n* = 2), posterior reversible encephalopathy (PRES) (*n* = 1), hemiconvulsion hemiplegia syndrome (HHS) (*n* = 1), and cerebellitis.Fig. 1Selected MRI images showing the spectrum of imaging abnormalities in Influenza-associated encephalitis/encephalopathy. A--I. A: Symmetrical diffusion restriction in the subcortical white matter and left thalamus (MRI: axial, DWI) in a 4 year old girl with acute encephalopathy with biphasic seizure disorder and late diffusion restriction (AESD) and Reye-like syndrome (Case 7). B: Symmetrical diffusion restriction posteriorly and left frontal lobe (MRI: axial, DWI) in a 2 year old girl with AESD (Case 9). C: Diffusion restriction in the left temporal lobe especially subcortical white matter (MRI: axial, DWI) in a 1.3 year old girl (Case 10). D: T2 hyperintensities in the posterior white matter (symmetrical) and patchy subcortical frontal white matter (MRI: axial T2 FLAIR) in a 7 year old boy with posterior reversible encephalopathy syndrome (Case 5). E: T2 hyperintensities in bilateral thalami which are swollen (MRI brain: axial, T2) in a 13 year old girl with acute necrotising encephalopathy. F: Prominent gadolinium enhancement of the cerebellar folia (MRI brain: axial, T1 with contrast) in a 6 year old girl (Case 6). G: Longitudinal T2 hyperintensity involving C3--7 (MRI cervical spine: sagittal, T2) in a 14 year old girl with encephalitis (Case 1). H: Diffusion restriction involving bilateral external capsule/claustrum (MRI: axial, DWI) in a 14 year old girl with encephalitis (Case 1). I: Diffusion restriction involving predominantly the right temporal lobe white matter (MRI brain: axial DWI) in a 1 year old boy with subcortical myoclonus (Case 11).Fig. 1

Genetic testing of Ran-binding protein 2 (RANBP2) was performed in the child with ANE ([Table 3](#tbl3){ref-type="table"} case 2) and the child who died from an ANE-like illness ([Table 3](#tbl3){ref-type="table"}, case 1). Both were negative. One child who met criteria for IAE was subsequently found to have a mutation in the polymerase gamma (POLG) gene ([Table 3](#tbl3){ref-type="table"}, case 11).

3.4. Treatment {#sec3.4}
--------------

Fourteen (66%) children were admitted to the ICU and nine (41%) required mechanical ventilation. Thirteen (59%) children received oseltamivir. Median time to commencement of oseltamivir from presentation was 1 day (mean 5.6 days, IQR 0--9 days), but \>3 days in five cases. Two ICU ventilated children were commenced on oseltamivir nine days after admission. In contrast, nineteen (86%) children were treated with a 3rd generation cephalosporin, while 14 (64%) received aciclovir. Nineteen (86%) received anticonvulsants and 16 (73%) continued these on discharge. First-line immunomodulatory treatment (corticosteroids and/or IVIg, plasmapheresis) was given to nine children with IAE (corticosteroids (*n* = 9), IVIg (*n* = 7) and plasmapheresis (*n* = 1)) but none of those with status epilepticus alone.

3.5. Outcomes {#sec3.5}
-------------

The median length of ICU and hospital stay was four days (range 1--37) and 8 days (range 2--108 days) respectively. Children with IAE were more likely to have both longer hospital (mean 33.5 days vs 4.8 days; *p* = 0.001) and PICU admissions (mean 7.7 days vs 2 days; *p* = 0.03) compared to children with status epilepticus. One child with IAE died following an ANE-like illness, although MRI findings were atypical ([Table 3](#tbl3){ref-type="table"}, case 1). Her post-mortem was inconclusive: showing generalised cerebral oedema and some features of acute hemorrhagic leucoencephalitis. Ten out of 11 children with IAE had an mRS score of 0 (normal) at baseline. At discharge from hospital 7/11 (64%) of children with IAE had a higher in mRS score (mRS \> 2; moderate disability) compared to those with status epilepticus. The change in mean mRS was significant between the two groups: children with IAE had a change in mRS of 3.1 points while those in the status epilepticus group had a mean increase of mRS of 0.4 points (*p*-value: 0.001). Nearly all children (7/8, 88%) with MRI diffusion restriction had a poor outcome. The child with MRI diffusion restriction and a good outcome had posterior reversible encephalopathy syndrome (PRES). Among the 7 children with IAE and a considerably elevated neopterin, four had an mRS \> 2 while three had mild deficits (mRS 1, 2 and 2). There was a mean increase in the mRS of 2.8 points the seven children with highly elevated CSF neopterin (74--669 nmol/L).

4. Discussion {#sec4}
=============

In this case series we observed two groups of children who presented with severe influenza related neurological disease. One group of children fulfilled criteria for IAE, while the other group, most often with pre-existing neurological disease, presented with status epilepticus but otherwise did not fulfill criteria for IAE. Amongst cases of IAE, elevated CSF neopterin appeared to correlate with the presence of diffusion restriction on MRI brain and adverse outcome. Use of oseltamivir was infrequent among all cases, although use of antibiotics occurred in the majority. Only one child had documented influenza vaccine, even amongst those with pre-existing neurological co-morbidity, despite the fact that this is recommended in Australia.[@bib13]

Influenza associated neurological complications are thought to occur due to an inflammatory or immune-mediated response to influenza infection rather than direct viral invasion.[@bib14], [@bib15] Among those with IAE we observed, similar to previous authors[@bib2], [@bib6], [@bib16] that CSF pleocytosis and detection of influenza in the CSF occurred in a minority (*n* = 5; 35%, and *n* = 1/4; 25%).[@bib3], [@bib7], [@bib17], [@bib18] However CSF neopterin, a biomarker of inflammation, was elevated in most children with IAE (*n* = 9, 81%). Neopterin, a catabolic product of guanosine triphosphate (GTP), is synthesized by human macrophages upon stimulation from interferon gamma and can be measured in urine, serum and CSF.[@bib19] While serum neopterin levels are useful in the diagnosis and monitoring of systemic infectious or inflammatory diseases, such as HIV,[@bib20] CSF neopterin, reflecting intrathecal production by microglial cells, more accurately detects CNS inflammatory diseases (infectious or immune mediated).[@bib11], [@bib19] A recent review assessing biomarkers of CSF inflammation found, among clinically available tests, that CSF neopterin performed better than the presence of oligoclonal bands or CSF pleocytosis in detection of CNS inflammation.[@bib21]

There is limited data regarding prognostically significant biomarkers in IAE. Pro-inflammatory cytokines may impair the blood brain barrier and induce apoptosis of neurons.[@bib14] Elevated cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha have been demonstrated in children with IAE and correlates with poorer outcome.[@bib14], [@bib22], [@bib23] Testing CSF IL-6 outside the research setting is currently unavailable. Clasmatodendrosis, abnormal morphological changes in astrocytes, occurring presumably due to the effect of pro-inflammatory cytokines, has recently been suggested to be a pathological feature of IAE on autopsy.[@bib24] Clasmatodendrosis was found in the cerebral white matter, thalamus, corpus callosum, cerebellum, thalamus and hippocampus of children with IAE and may correlate MRI changes commonly seen.[@bib24] Previous authors have associated abnormalities on MRI brain with poorer outcome.[@bib7] In our cohort MRI brain abnormalities were diverse and common, particularly diffusion restriction in the subcortical white matter. Diffusion restriction correlated with a poor outcome, apart from in the child who had PRES, and was associated with an elevated CSF neopterin in most cases. Further studies of IAE are required to evaluate whether significant elevations of CSF neopterin, particularly in combination with diffusion restriction and other MRI changes, could predict short and long-term outcome.

Oseltamivir, a neuramidase inhibitor which prevents release of influenza virus from infected cells[@bib25] has been shown to reduce influenza symptoms in otherwise healthy children by 29 h (95% CI 12--47 h,*p* = 0.001).[@bib26] Only 59% (13 children) were treated with oseltamivir and there was a significant delay in commencement in 5 cases (\>3 days in hospital). In contrast, empirical 3rd generation cephalosporin (86%) and aciclovir use (64%) was more frequent. This may be related to the perception among practitioners that anti-influenza therapy has little benefit. We suggest in accordance with local guidelines,[@bib8] that children with encephalitis should be empirically treated with oseltamivir during the influenza season (May to October). The evidence for use of immunotherapy (IVIg, corticosteroids) in IAE, is limited[@bib27], [@bib28] however, in our case series, most children with IAE were treated with first-line immunotherapy with uncertain benefit. No serious side effects were reported.

In 2017, the burden of influenza in Australia (particularly the Eastern states) was the highest seen since the 2009 pandemic.[@bib8] Based on IAE incidence estimates published by Britton et al.[@bib2] from the 2013--15 influenza seasons in Australia and the population coverage of our hospitals, we calculated that we would expect 5.2 (1.3--14.5) cases of IAE in children (\<14 years) per year. The IAE case frequency observed in our cohort was twice the expected point estimate based on these previous incidence estimates but within the 95% confidence interval,[@bib2] and so contribute to validating the estimates from Britton et al.[@bib2]

The short-term outcome of our cohort, particularly those with IAE, was alarming with 64% having a poor outcome. While there was a significant rate of ICU admission among the group of children with status epilepticus (45%) this was not as high as children with IAE (82%) and, most often, non-IAE children did not experience a significant change in their mRS. This supports previous observations that survivors of IAE during the 2009 H1N1 pandemic, and in more recent non-pandemic influenza seasons in Australia, experienced significant ongoing disability.[@bib29], [@bib30] We have previously shown in a large retrospective encephalitis cohort study that ICU admission, MRI diffusion restriction and status epilepticus and were risk factors for a long-term abnormal outcome.[@bib31] These risk factors were common (82%, 73%, 45%) in children with IAE from our cohort. The medium and long-term outcome in our cohort should be assessed including formal neuropsychological testing. Further research is required to understand and modulate the CNS inflammatory cascade present in IAE in order to modulate long term neurodisability.

The overall influenza immunisation rate during 2017 in Australia was low at 33%,[@bib32] however a recently observed rate of vaccine receipt among children was even lower at 17.1%.[@bib33] Four age-specific quadrivalent influenza vaccines containing two strains of Influenza A (H1N1 \[Michigan\] and H3N2 \[Hong Kong\]) and two strains of influenza B (Brisbane and Phuket) were available in 2017. Children older than six months were eligible to be vaccinated and the vaccine was provided free to children with neurological disease.[@bib34] In our cohort just one child had a documented influenza vaccination, although a third of children were eligible for free immunisation and the remainder could have received an immunisation at the cost of around \$20--50 AUD. We emphasise that the severe syndromes and adverse outcomes observed here should be considered preventable. Following high rates of influenza related morbidity in 2017(including these cases), New South Wales and other Australian states have introduced universal funded seasonal influenza immunisation to all children aged 6 months to 5 years.[@bib35]

Our series has limitations. We describe children with severe influenza-associated neurological complications but did not include children with mild neurological complications. Children with pre-existing epilepsy may not have always been tested for influenza and may be under-represented. The collection of clinical data was retrospective, and some electronic data were incomplete. Seasonal influenza immunisation status was not always clearly recorded, although we reviewed the Australian immunisation register to verify vaccination status where possible. Influenza sub-typing from NPA samples and CSF influenza PCR testing was not routinely performed. In the SE group, CSF studies, including CSF neopterin were performed infrequently and MRI brain infrequently requested. Due to this we were unable to use this group as a direct control for the finding of elevated CSF neopterin the IAE group. Serial CSF neopterin to assess treatment and clinical progress were not performed.

5. Conclusion {#sec5}
=============

This is the first series to demonstrate that elevation of CSF neopterin, a marker of CNS inflammation, occurs commonly in children with IAE. CSF neopterin may be a useful diagnostic marker for IAE while its role as a prognostic marker requires further evaluation. MRI diffusion restriction was associated with a poor outcome in IAE. Short-term outcomes of children with neurological complications of influenza, especially within the IAE group, were alarming, with nearly two-thirds of children having a poor outcome despite receipt of ICU support, anticonvulsants, first-line immunotherapy and, in some, anti-viral treatment. Given the severity of influenza associated neurological complications, we recommend a "treat and test" approach to the use of oseltamivir in children presenting with acute encephalopathy/encephalitis during the influenza season. Finally, seasonal influenza vaccination should be universally provided to children and those at risk of severe influenza, with better education and awareness to increase uptake in the paediatric population.
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The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejpn.2018.09.009>.

[^1]: Note: tests used -- Fisher exact for categorical and Mann--Whitney for continuous data points.

[^2]: IAE: influenza related encephalopathy.

[^3]: SE: Status epilepticus.

[^4]: NPA: Nasopharyngeal aspirate.

[^5]: Including one borderline result (33.86 nmol/L).

[^6]: Borderline result (31.75 nmol/L).

[^7]: Tests used -- Fisher exact for categorical and Mann--Whitney for continuous data points.

[^8]: IAE: influenza related encephalopathy.

[^9]: SE: status epilepticus.

[^10]: Treatment received during hospital admission.

[^11]: Defined as an increase of more than 2 points on mRS (new disability or worsening of preexisting disability by \>2 points).

[^12]: ANE, acute necrotizing encephalopathy; AESD, acute encephalopathy with biphasic seizure disorder and late diffusion restriction; ADEM, acute disseminated encephalomyelitis; HHS, hemconvulsion hemiplegic syndrome; ICU, intensive care unit, POLG, polymerase gamma, PRES, posterior reversible encephalopathy syndrome. MOG, myelin oligodendrocyte glycoprotein; NMDAR, N-methyl-[d]{.smallcaps}-aspartate antibody; VGKC, voltage gated potassium channel antibody; GAD, glutamic acid decarboxylase antibody; TPO, thyroperoxidase antibody; NMO, neuromyelitis optica antibody; PCA1, purkinje cell cytoplasmic antibody 1; PCA2, purkinje cell cytoplasmic antibody 2.
